In conclusion, our results demonstrate that pab-miR396a-5p delivered by PLEVPs could directly target HSP83a (HSP90) involved in the IL-17 signaling pathway, providing a potential mechanism for therapeutic effects of PLEVPs on psoriasis. This evidence concerns the gene IL17A and psoriasis.